# Data Visualization Reviewer — visual_gpt

**Model:** openai/gpt-4o  
**Date:** 2026-04-15  
**Tokens:** 8004 input / 1016 output  
**Duration:** 12.5s  

---

# Data Visualization Reviewer — Safety Review

## Executive Summary
The MMR for study DNLI-I-0001 encompasses a rigorous safety profile analysis of pediatric patients with MPS IIIA treated with DNL-126. Safety signals such as infusion-related reactions (IRRs) and anti-drug antibodies (ADAs) were prominent but expected. Overall, the safety risk appears manageable with existing monitoring protocols, but several data visualization and reporting improvements are advised to ensure regulatory compliance and clinical clarity.

## Findings

### Visualization Compliance with Regulatory Standards
- **Priority:** CRITICAL
- **Confidence:** HIGH
- **Section(s):** All figures
- **Description:** Several figures lack annotation and clear labeling to meet FDA/EMA guidance for safety data presentation. Consistent formatting and adequate explanatory notes are absent, which may hinder accurate interpretation by reviewers.
- **Recommendation:** Ensure all figures are labeled with units and scales, and provide comprehensive figure legends to clarify data context. Consistency in color schemes for IRRs and ADA events is critical.

### Concordance Between Figures and Tables
- **Priority:** HIGH
- **Confidence:** HIGH
- **Section(s):** Sections 2, 4, 5
- **Description:** Discrepancies noted between tabular data on participant demographics and ADA status versus corresponding graphical representations, specifically Figure 4.2.
- **Recommendation:** Verify and cross-check all figures against tables in the dataset to ensure accuracy. Any deviations should be immediately investigated and corrected.

### Representation of Safety Signals
- **Priority:** HIGH
- **Confidence:** HIGH
- **Section(s):** Sections 5, 6, 7
- **Description:** IRR event visualization (Figure 4.1, 4.2) tends to under-represent the clinical severity and frequency by mere tally marks. Cardiovascular safety data in Figures 7.1-7.4 are also overly simplified.
- **Recommendation:** Use stacked bar charts or severity-graduated markers to represent the IRR events and overlay clinical severity on the ECG trend plots for enhanced clarity.

### Missing Visualizations
- **Priority:** HIGH
- **Confidence:** MODERATE
- **Section(s):** Section 3, Appendix
- **Description:** Cohort-specific safety data on vitals and hepatotoxicity were presented in text but lacked accompanying visualizations (e.g., time-to-event plots).
- **Recommendation:** Incorporate Kaplan-Meier or time-to-event visualization for SAEs and lab trends to highlight potential temporal patterns and correlations.

### Clinical Relevance and Risk Communication
- **Priority:** MEDIUM
- **Confidence:** HIGH
- **Section(s):** Sections 6, 8
- **Description:** The use of advanced statistical measures (confidence intervals, statistical significance) is not apparent in trend plots, reducing the outputs' clinical informational value.
- **Recommendation:** Apply appropriate statistical annotations to lab and vitals plots to underline clinically relevant value changes.

### Data Audit Trail Evaluation
- **Priority:** MEDIUM
- **Confidence:** HIGH
- **Section(s):** Appendix, Delta Tracker
- **Description:** Insufficient documentation of the data corrections or adjustments over different cuts, which potentially impacts traceability of safety issues.
- **Recommendation:** Implement a more robust version control system for data cuts, detailing changes extensively in audit trails for each modification.

### Publication-Quality Assurance
- **Priority:** LOW
- **Confidence:** MODERATE
- **Section(s):** All sections
- **Description:** While figures are generally clear in isolation, integration into a cohesive report with linguistic proofreading felt superficial, impacting the overall professionalism.
- **Recommendation:** Undertake a single-pass review for grammatical errors and style consistency to ensure it meets publication standards.

## Risk Assessment Matrix
| Domain           | Risk Level | Key Signal                           | Action Required            |
|------------------|------------|--------------------------------------|----------------------------|
| IRR Management   | HIGH       | High incidence of IRRs               | Reassessment of prophylaxis|
| Hepatotoxicity   | LOW        | No Hy's Law cases                    | Regular monitoring         |
| Cardiovascular   | MEDIUM     | QTcF prolongation incidents          | Enhanced ECG monitoring    |
| Immunogenicity   | HIGH       | High ADA prevalence                  | Titer-based dose adjustment|

## Summary Recommendations
1. **Enhance Figure Compliance**: Ensure all visualizations align with regulatory standards, enhancing clarity and interpretability.
2. **Verify Table-Figure Alignment**: Conduct stringent checks to ensure accord between tabular data and graphic representations.
3. **Incorporate Additional Visualizations**: Add time-to-event and cohort-specific plots to better capture safety trends and associations.
4. **Improve Visualization of IRR Severity**: Use more informative visual indications of IRR severity to enable swift recognition by healthcare professionals.
5. **Upgrade Data Tracking Mechanisms**: Standardize audit trails with comprehensive commentary on dataset evolution to maintain integrity through data cuts.